Status:
COMPLETED
Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization
Lead Sponsor:
Novartis
Conditions:
Macular Degeneration
Choroidal Neovascularization
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durabili...
Eligibility Criteria
Inclusion
- Subjects of either gender age 50 years or older
- Subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD)
Exclusion
- Choroidal neovascularization due to causes other than AMD
- Prior treatment for neovascular AMD in the study eye
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2009
Estimated Enrollment :
321 Patients enrolled
Trial Details
Trial ID
NCT00436553
Start Date
February 1 2007
End Date
October 1 2009
Last Update
April 19 2011
Active Locations (43)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Tucson, Arizona, United States, 85704
2
Novartis Investigative Site
Beverly Hills, California, United States, 90211
3
Novartis Investigative Site
Oakland, California, United States, 94609
4
Novartis Investigative Site
Pasadena, California, United States, 91105-3153